What Makes BioMarin (BMRN) so Attractive

BioMarin Pharmaceutical (NASDAQ:BMRN) is one of the 17 biotechnology stocks with more than 50% upside.

As of February 12 closing, BioMarin Pharmaceutical (NASDAQ:BMRN) carried a moderately bullish analyst sentiment. Of the 15 analysts covering the stock, 10 assigned Buy ratings and 5 issued Hold ratings. With no Sell rating, the stock has a projected median 1-year price target of $88.29, implying more than 47% upside.

Copyright: nexusplexus / 123RF Stock Photo

On February 6, Allison Bratzel from Piper Sandler reiterated her Overweight rating on BioMarin Pharmaceutical (NASDAQ:BMRN). The analyst reduced her price target on the stock from $122 to $84. Despite this downward revision, her estimates still imply upside potential of more than 40% from the prevailing level. Bratzel’s rating incorporates recent fourth-quarter pre-releases, which also prompted Piper Sandler to adjust its estimates and price targets for some commercial names.

BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes targeted therapies for life-threatening medical conditions and rare genetic diseases. Some of its major products include VIMIZIM, VOXZOGO, NAGLAZYME, and ALDURAZYME. The company operates in more than 70 countries and currently has several drugs in the development stage.

While we acknowledge the risk and potential of BMRN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BMRN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.